Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate Update

PMA submission targeted for Q1 2026 following positive Tigris results and ongoing FDA interactionsCompany to host Corporate Update call on Wednesday, December 10, 2025 TORONTO, Nov. 07, 2025 (GLOBE ...

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept ...